Cargando…
First-in-Human Evaluation of Positron Emission Tomography/Computed Tomography With [(18)F]FB(ePEG12)12-Exendin-4: A Phase 1 Clinical Study Targeting GLP-1 Receptor Expression Cells in Pancreas
Pancreatic β-cell mass (BCM) has a central importance in the pathophysiology of diabetes mellitus. Recently, pancreatic β-cell-specific imaging, especially positron emission tomography (PET) with exendin-based probes, has emerged for non-invasive evaluation of BCM. We developed a novel exendin-based...
Autores principales: | Fujimoto, Hiroyuki, Fujita, Naotaka, Hamamatsu, Keita, Murakami, Takaaki, Nakamoto, Yuji, Saga, Tsuneo, Ishimori, Takayoshi, Shimizu, Yoichi, Watanabe, Hiroyuki, Sano, Kohei, Harada, Norio, Nakamura, Hiroshi, Toyoda, Kentaro, Kimura, Hiroyuki, Nakagawa, Shunsaku, Hirai, Mitsuharu, Murakami, Atsushi, Ono, Masahiro, Togashi, Kaori, Saji, Hideo, Inagaki, Nobuya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417326/ https://www.ncbi.nlm.nih.gov/pubmed/34489868 http://dx.doi.org/10.3389/fendo.2021.717101 |
Ejemplares similares
-
Distinctive detection of insulinoma using [(18)F]FB(ePEG12)12-exendin-4 PET/CT
por: Murakami, Takaaki, et al.
Publicado: (2021) -
(18)F-labeled PEGylated exendin-4 imaging noninvasively differentiates insulinoma from an accessory spleen: the first case report of [18F]FB(ePEG12)12-exendin-4 positron emission tomography/computed tomography for insulinoma
por: Sakaki, Kentaro, et al.
Publicado: (2023) -
Investigation of the preservation effect of canagliflozin on pancreatic beta cell mass using SPECT/CT imaging with (111)In-labeled exendin-4
por: Hamamatsu, Keita, et al.
Publicado: (2019) -
Association of glucagon‐like peptide‐1 receptor‐targeted imaging probe with in vivo glucagon‐like peptide‐1 receptor agonist glucose‐lowering effects
por: Murakami, Takaaki, et al.
Publicado: (2020) -
Initial evaluation of PET/CT with (18)F‐FSU‐880 targeting prostate‐specific membrane antigen in prostate cancer patients
por: Saga, Tsuneo, et al.
Publicado: (2019)